Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;3(5):321-30.

A comparison of drug formularies and the potential for cost-savings

Andrea L Kjos  1 , Jon C Schommer  2 , Yingli Yuan  3
Affiliations

A comparison of drug formularies and the potential for cost-savings

Andrea L Kjos et al. Am Health Drug Benefits. 2010 Sep.

Abstract

Background: Brand-name drug costs have been escalating in the United States, and the reasons for this are not immediately clear. A lack of adequate and accurate information about drug effectiveness, safety, and cost has implications for drug utilization and cost.

Objective: To explore the extent to which health plan formularies were consistent with recommended drug listings and identify what would be the potential cost-savings on total drug expenditures if the utilization rate of the recommended therapies was increased.

Method: This study compared publicly available recommended drug listings with the formularies of 8 major health plans in Minnesota. Data from 1 of the health plans underwent an in-depth case analysis to evaluate the potential impact on pharmaceutical expenditures, using increased utilization rate scenarios of the recommended drugs.

Results: Health plans were similar with respect to degree of coverage for the recommended drugs. However, the case analysis showed that by increasing the utilization rate of recommended drugs, a potential cost-savings of more than 50% could be realized for the evaluated health plan for some therapeutic categories.

Conclusion: This study demonstrates an approach to assessing drug formularies using publicly available, recommended drug lists that incorporated evidence for effectiveness, safety, and cost. By using the application of this type of reliable information, formulary changes can be guided to incentivize value-based utilization for patient populations.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cumulative Percentage of Recommended Therapeutic/Drug Coverage, by Health Plan (A-H)
Figure 2
Figure 2. Total Cost and Potential Cost-Savings with 85% and 100% Recommended Drug Utilization, $
None
Andrea L. Kjos
See this image and copyright information in PMC

References

    1. Gross D, DeLeno Neuworth D, eds. Average manufacturer price increases for widely used brand name and specialty prescription drugs reach record levels. AARP Rx Watchdog Rep. April 2009;1–3 http://assets.aarp.org/www.aarp.org_/cs/health/rx_watchdog_apr09.pdf. Accessed January 4, 2010.
    1. Schondelmeyer SW. Statement on prescription drug price inflation: are prices rising too fast? Statement before Subcommittee on Health, Congress of the United States House of Representatives, December 8, 2009. http://energycommerce.house.gov/Press_111/20091208/schondelmeyer_testimo.... Accessed January 4, 2010.
    1. Kemp K; for the Office of the Assistant Secretary for Planning and Evaluation, US Department of Health & Human Services. Conference summary: pharmaceutical pricing practices, utilization, and costs. http://aspe.hhs.gov/health/reports/Drugpapers/kemp1.htm. Accessed January 4, 2010.
    1. Kleinke JD. The price of progress: prescription drugs in the health care market. Health Aff (Millwood). 2001; 2: 43–60. - PubMed
    1. Kohl H, Shrank WH. Increasing generic drug use in Medicare Part D: the role of government. J Am Geriatr Soc. 2007; 55: 1106–1109. - PubMed

LinkOut - more resources